Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Nov;42(11):3168-75.
doi: 10.1161/STROKEAHA.111.620831. Epub 2011 Sep 8.

Isoflavone soy protein supplementation and atherosclerosis progression in healthy postmenopausal women: a randomized controlled trial

Howard N Hodis  1 , Wendy J Mack, Naoko Kono, Stanley P Azen, Donna Shoupe, Juliana Hwang-Levine, Diana Petitti, Lora Whitfield-Maxwell, Mingzhu Yan, Adrian A Franke, Robert H Selzer; Women's Isoflavone Soy Health Research Group
Collaborators, Affiliations
Randomized Controlled Trial

Isoflavone soy protein supplementation and atherosclerosis progression in healthy postmenopausal women: a randomized controlled trial

Howard N Hodis et al. Stroke. 2011 Nov.

Abstract

Background and purpose: Although epidemiological and experimental studies suggest that dietary intake of soy may be cardioprotective, use of isoflavone soy protein (ISP) supplementation as a primary preventive therapy remains unexplored. We determined whether ISP reduces subclinical atherosclerosis assessed as carotid artery intima-media thickness progression.

Methods: In a double-blind, placebo-controlled trial, 350 postmenopausal women 45 to 92 years of age without diabetes and cardiovascular disease were randomized to 2 evenly divided daily doses of 25 g soy protein containing 91 mg aglycon isoflavone equivalents or placebo for 2.7 years.

Results: Overall, mean (95% CI) carotid artery intima-media thickness progression rate was 4.77 (3.39-6.16) μm/year in the ISP group and 5.68 (4.30-7.06) μm/year in the placebo group. Although carotid artery intima-media thickness progression was reduced on average by 16% in the ISP group relative to the placebo group, this treatment effect was not statistically significant (P=0.36). Among the subgroup of women who were randomized within 5 years of menopause, ISP participants had on average a 68% lower carotid artery intima-media thickness progression rate than placebo participants 2.16 (-1.10 to 5.43) versus 6.79 (3.56-10.01) μm/year (P=0.05). ISP supplementation had a null effect on women who were >5 years beyond menopause when randomized. There were no major adverse events from ISP supplementation.

Conclusions: ISP supplementation did not significantly reduce subclinical atherosclerosis progression in postmenopausal women. Subgroup analysis suggests that ISP supplementation may reduce subclinical atherosclerosis in healthy young (median age, 53 years) women at low-risk for cardiovascular disease who were <5 years postmenopausal. These first trial results of their kind warrant further investigation.

Trial registration: ClinicalTrials.gov NCT00118846.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Women’s Isoflavone Soy Health (WISH) trial flow for carotid artery intima-media thickness outcome.
Figure 2
Figure 2
Carotid artery intima-media thickness progression rates estimated by linear mixed models (by treatment group) with numbers of subjects evaluated at each follow-up ultrasound scanning time; p=0.35 for difference between treatment groups. ISP = isoflavone soy protein treatment group.
See this image and copyright information in PMC

References

    1. Spencer Gregory., editor. U.S. Bureau of the Census Population Reports. Series P-25, No. 1018, Projections of the Population of the United States, by Age, Sex, and Race: 1988 to 2080. U.S. Government Printing Office; Washington, D.C.: 1989.
    1. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs and patterns of use. N Engl J Med. 1993;328:246–252. - PubMed
    1. Stadberg E, Mattsson LA, Milsom I. The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population. Acta Obstet Gynecol Scand. 1997;76:442–448. - PubMed
    1. Kuiper GGJM, Carlson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology. 1997;138:863–870. - PubMed
    1. Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology. 1998;139:4252–4263. - PubMed

Publication types

Associated data